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Abstract
Pancreatic neuroendocrine tumours (pNETs) represent rare 
neoplasms of all NETs often presenting without functional 
activity. Many sporadic non-functioning pNET patients are 
already metastatic at the time of diagnosis, and the thera-
peutic approach to such patients is mostly palliative. In this 
international, multicentre, retrospective cohort study, we as-
sessed the prognostic value of a set of anthropometric, clin-
ical, biochemical, radiological and pathological parameters 
at baseline and the impact of the therapeutic strategies on 
the survival of patients with sporadic grade 1/2, stage IV, 
non-functioning pNETs. Three hundred and twelve consecu-
tive patients diagnosed between 1993 and 2010 were in-
cluded. The median overall survival (OS) was 6.6 years and 
survival at 5 and 10 years was 62 and 34% respectively. On 
univariate analysis, Eastern Cooperative Oncology Group 
(ECOG) status ≥2, grade 2, bilobar hepatic metastases, syn-
chronous metastases, and high chromogranin A, alkaline-
phosphatase and lactic-dehydrogenase were associated 
with a significant reduction of OS. Palliative/curative surgery 
and loco-regional hepatic interventions were significant fac-
tors improving OS. On multivariate analysis, ECOG status ≥2, 
synchronous metastases, Ki-67 ≥10%, and high alkaline-
phosphatase correlated significantly with an increased risk 
of death. Both palliative/curative surgery and loco-regional 
hepatic interventions had a positive impact on OS. Although 
most parameters did not prove to be independent OS pre-
dictors at multivariate analysis, they showed a tendency to-
wards that. Future prospective studies including larger pa-
tient populations may give greater clarity. We believe the 
integration of these parameters has the potential to provide 
a reliable prognostic score for the stratification of patients 
with sporadic well-differentiated metastatic non-function-
ing pNETs. © 2018 S. Karger AG, Basel
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Introduction
Pancreatic neuroendocrine tumours (pNETs) are rare 
neoplasms accounting for about 2–5% of all pancreatic 
tumours [1–3]. These tumours are characterized by clin-
ical and behavioural heterogeneity, with roughly 60–90% 
of them presenting without hormone hypersecretion syn-
drome and being defined as non-functioning pNETs [4, 
5]. Also, due to their often-indolent clinical manifesta-
tions, a large number of non-functioning pNET patients 
present with metastatic disease at the time of diagnosis. 
The majority of pNETs are sporadic; however, they may 
also occur in the setting of various inherited syndromes, 
including multiple endocrine neoplasia type 1, Von Hip-
pel-Lindau disease, neurofibromatosis type 1, and tuber-
ous sclerosis [6]. While pNETs associated with familial 
syndromes are usually more indolent than their sporadic 
counterparts, pNET patients with an inherited disease are 
at higher risk of developing multifocal tumours and, con-
sequently, require different therapeutic and follow-up 
strategies [6]. Despite the high rate of liver metastases at 
the time of the diagnosis, non-functioning pNETs are as-
sociated with a more favourable prognosis compared to 
most gastrointestinal malignancies and the overall sur-
vival at 5 years (5yOS) is estimated to be around 30–60%, 
depending on the centre treated [1, 2, 7].
The therapeutic approaches currently available for the 
treatment of metastatic pNETs are different from cura-
tive surgery, primary tumour resection or palliative strat-
egies to control symptoms and, possibly, improve patient 
survival [8, 9]. In a study on patients with a metastatic 
pNET, an aggressive therapeutic strategy appeared to be 
associated with more favourable outcomes, with a medi-
an OS of 4.8 years in patients who underwent aggressive 
surgery versus 1 year in those who did not undergo resec-
tion [1]. However, only a small proportion of patients 
with metastatic non-functioning pNETs are suitable can-
didates for surgical resection of their primary tumour or 
liver metastases, and this may significantly affect the 
overall prognosis of pNET patients. A careful multidisci-
plinary evaluation of patients can help identify those who 
are more likely to benefit from an aggressive therapeutic 
approach with regard to OS [4, 10]. However, in other 
studies, and in an extensive review of the literature, less 
clear conclusions have been drawn and the value of an 
aggressive rather than conservative therapeutic approach 
still appears to be undefined [11, 12]. In practice, the 
prognosis of pNET patients cannot be easily predicted 
and opting for a more conservative strategy, including a 
wait-and-see approach, rather than aggressive manage-
ment is still a matter of debate among the experts [9]. 
Some decision-making aids have been entitled compris-
ing tumour load, proliferation index, rapid tumour prog-
ress and symptomatic disease [7]. However, there are no 
unequivocal data in the literature indicating which labo-
ratory measures, radiological features, or patient charac-
teristics may be reliable prognostic factors and able to di-
rect therapeutic decisions. Recently, a prognostic model 
based on mitotic rate and functional status has been 
shown to correlate with pNET patient OS [13]. In patients 
who underwent surgery, high pre-operative chromo-
granin A (CgA) was negatively associated with disease-
free survival and OS and appeared to be the only indepen-
dent predictor of disease-free survival in that cohort of 
patients [14]. The validity of CgA as a prognostic tool was 
also reported in a study from China on a series of patients 
with non-functioning pNETs and liver metastases [15]. 
As predictors of survival, both the American Joint Com-
mittee on Cancer and the European Neuroendocrine Tu-
mor Society (ENETS) TNM- classification appear to have 
a prognostic value in different patient populations [16, 
17]. In a study from Italy, the OS of gastroenteropancre-
atic NET patients after resection of the primary tumour 
correlated with both patient age and World Health Orga-
nization (WHO) 2010 staging (which strongly depends 
on Ki-67 proliferation index), but not with the site of the 
primary tumour [18]. A retrospective study from Norway 
involving 114 patients with well-differentiated pNETs 
showed that Ki-67 > 2%, high CgA levels, presence of dis-
tant metastases and palliative treatment were associated 
with poor OS [19].
In this international, multicentre, retrospective cohort 
study, we have evaluated the prognostic value of a set of 
baseline anthropometric, clinical, biochemical, radiolog-
ical and pathological parameters and the impact of the 
treatment modalities on the survival of patients with spo-
radic well-differentiated metastatic non-functioning 
pNETs, with the goal of building up a clinical risk strati-
fication tool for prognostic assessment.
Materials and Methods
Study Design
The inclusion criteria were pathologically confirmed well-dif-
ferentiated, grade 1 or 2 (Ki-67 index ≤20%), advanced pNETs and 
metastatic disease (stage IV) diagnosed between 01 January 1993 
and 01 January 2010. The minimum follow-up period was 5 years. 
Familial and syndromic pNETs were excluded (e.g., multiple en-
docrine neoplasia type 1), as well as those with secondary malig-
nancy. This study has been carried out in accordance with the prin-
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Variables
Data collected included demographics (name of centre, age at 
diagnosis, gender, Eastern Cooperative Oncology Group perfor-
mance status [ECOG-PS], date of initial diagnosis, date of diagnosis 
of metastatic disease); clinical presentation (primary tumour site 
[head, body, tail of pancreas], site of metastases, location of hepatic 
metastases according to liver lobes [right, left or both lobes], func-
tionality, type of functionality, synchronous versus metachronous 
metastases, Ki-67 and mitotic index); laboratory parameters (biliru-
bin, alkaline phosphatase [AP], lactate dehydrogenase [LDH], albu-
min, creatinine, CgA]); treatment and date of last follow-up or death. 
Synchronous metastasis was defined as occurring within the first year 
after initial diagnosis. The exact date of diagnosis of metastatic dis-
ease was correlated with the first imaging study giving evidence of 
metastatic spread. Data on Ki-67 was obtained from the time of initial 
diagnosis; in case of metachronous metastases the most current Ki-
67 data was used. Therapeutic interventions included surgery, sys-
temic treatment and loco-regional hepatic therapy. Surgery was de-
fined as curative when all of the primary tumour and metastases were 
removed (R0-Status), or as palliative (R1- or R2-Status). Surgical 
therapy included both operation and radiofrequency ablation. Sys-
temic treatment involved medical therapy (somatostatin analogues, 
chemotherapy and molecular-targeted therapy) and peptide recep-
tor radionuclide therapy (PRRT). Loco-regional therapy included 
transarterial embolization, transarterial chemoembolization and se-
lective internal radiation therapy. Laboratory parameters were docu-
mented closest to the date of diagnosis of metastatic disease. For each 
laboratory parameter, data collected were: absolute value, normal 
range and the category (normal or elevated).
Outcomes and Statistical Methods
The association of categorical variables was assessed by the chi 
square test or Fisher’s exact test. Continuous variables were ex-
pressed as medians with ranges. Outcomes calculated were OS, l, 5 
and 10yOS. OS was calculated as the time elapsed from the date of 
diagnosis of metastatic disease to the date of death or last follow-up 
in living patients. Five and 10yOS was the percentage of patients who 
were alive 5 and 10 years, respectively, after the diagnosis of meta-
static disease. Survival was estimated according to the Kaplan-Meier 
product limit method accompanied by the 95% CI. Comparisons 
between OS for levels of the relevant clinical covariates were per-
formed using the log-rank test. A p value of < 0.05 was considered 
statistically significant. Univariate and multivariate analyses using 
the Cox proportional hazards model were carried out to identify co-
variates independently associated with prognosis. The CIs for the 
regression coefficients were based on the Wald statistic. Only vari-
ables with a p value of < 0.10 at univariate analysis were introduced 
in the Cox model. Relative risks were expressed as hazard ratios (HR) 
with corresponding p values. All statistical analyses were performed 
using R version 3.2.3 (The R Foundation for Statistical Computing 
platform).
Results
This was a retrospective, international, multicentre 
study on prognostic parameters in patients with well-dif-
ferentiated, metastatic pNETs. The present study in-
volved 6 tertiary referral centres from Germany, Ireland, 
Table 1. Characteristics of patients, tumours and treatments
Characteristic n %
Gender, male 180 57.69
Age, >50 years 204 65.38
ECOG* PS, ≥2 20 6.41
Histological grade
Grade 1 99 31.73
Grade 2 202 64.74
Not reported/missing 11 3.53





Right lobe 21 6.73
Left lobe 19 6.09
Both lobes 215 68.91
Not reported/missing 57 18.27
Extra-hepatic metastases






Curative intention 33 10.6
Palliative intention 96 30.8
No 140 44.87

































PS, performance status; CgA, chromogranin A; AP, alkaline phos-
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Spain, the Netherlands, Brazil and Colombia. Patients 
were identified from hospital records and databases, and 
were included consecutively from 1993 to 2010. The cut-
off date for follow-up was April 1, 2015. A total of 312 
metastatic pNET patients met the inclusion criteria. Pa-
tient baseline characteristics are shown in Table 1. There 
were 180 male patients included (58%), while 204 patients 
were older than 65 years (65%). Only a minority present-
ed an ECOG ≥2 (n = 20; 6%) at diagnosis. Most patients 
revealed a synchronous metastatic disease (n = 276; 88%) 
with well-differentiated tumours G2 (n = 202; 65%). 
When assessing hepatic tumour burden, some patients 
were diagnosed with unilateral liver involvement (7% 
right lobe, 6% left lobe); however approximately two 
thirds presented with bilobar disease (n = 215; 69%). Be-
yond liver metastases lymph node involvement was the 
most common extra-hepatic tumour manifestation (n = 
91; 29%). Furthermore, treatment details are listed in Ta-
ble 1. One hundred forty patients received no surgery 
(45%), but out of 129 patients with surgery 33 patients 
(11%) were resected in a curative intent and 96 (31%) in 
a palliative approach. A systemic intervention including 
biotherapy, chemotherapy, targeted treatments and 
PRRT was applied to 80% of patients (n = 249) and loco-
regional treatment was offered in 47 cases (15%). Median 
OS was estimated to be 6.6 years (95% CI 5.8–8.1; Fig. 1). 
The proportion of patients who were alive at 5 and 10 
years’ follow-up was 62 and 34% respectively.
With univariate Kaplan-Meier analysis, the following 
variables were associated with a statistically significant 
reduction in OS: ECOG-PS ≥2 versus < 2 (median OS: 2.7 
vs. 8.5 years, p < 0.0001); grade 2 versus 1 (median OS: 
5.7 vs. 9.4 years, p < 0.0001); bilobar compared with uni-
OS
Patients at risk:
Median (95% CI): 6.6 (5.8–8.1) years
5 Years (95% CI): 62.4 (56.6–68.1) %
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285 163 44 8 5 2
Time, years
Fig. 1. Median overall, 5 years’ and 10 years’ 
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Fig. 2. Therapeutic interventions in pNET patients as significant 
prognostic factors for survival from univariate analysis. a The me-
dian OS was 18.5, 10.0 and 4.6 years for curative surgery, palliative 
surgery and no surgery groups respectively. b Loco-regional treat-
ment resulted in a significant prolonged OS compared with not 
performed (median OS 9.4 vs. 6.8 years, HR 0.63, 95% CI 0.39–
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lobar hepatic metastases (median OS: 6.3 vs. 8.5 years, 
p = 0.035); synchronous vs metachronous metastases 
(median OS: 5.9 vs. 12.8 years, p = 0.002); elevated versus 
normal basal CgA (median OS: 5.8 vs. 8.8 years, p = 
0.008); elevated vs. normal AP (median OS: 3.1 vs. 8.3 
years, p < 0.0001); and elevated vs. normal LDH (median 
OS: 2.7 vs. 7.6 years, p = 0.013). Univariate analysis also 
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Fig. 3. Selection of different parameters in pNET patients as sig-
nificant prognostic factors for survival from univariate analysis. a 
ECOG-PS ≥2 versus < 2: the median OS was 2.7 vs. 8.5 years (HR 
3.0, 95% CI 1.8–5.1, p < 0.0001). b Grade 2 versus 1: the median 
OS was 5.7 vs. 9.4 years (HR 1.9, 95% CI 1.3–2.6, p < 0.0001). c 
Hepatic metastases: the median OS was 8.5 years for one lobe com-
pared with 6.3 years for both lobes (HR 1.7, 95% CI 1.04–2.9, p = 
0.035, Wald test). d CgA: the median OS was 8.8 years for normal 
level compared with 5.8 for elevated level (HR 1.9, 95% CI 1.2–2.9, 
p = 0.008, Wald test). e Alkaline Phosphatase: the median OS was 
8.3 years for normal level compared with 3.1 for elevated level (HR 
1.7, 95% CI 1.6–3.1, p < 0.0001, Wald test). f LDH: the median OS 
was 7.6 years for normal level compared with 2.7 for elevated level 
(HR 1.6, 95% CI 1.1–2.4, p = 0.013, Wald test). OS, overall sur-
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tention) and loco-regional hepatic interventions as sig-
nificant prognostic factors (Fig. 2, 3).
Using multivariate Cox analysis, the following vari-
ables showed a statistically significant increase in risk of 
death: ECOG-PS ≥2 (HR 2.02, p = 0.012), synchronous 
metastases (HR 2.14, p = 0.036); Ki-67 index ≥10% (HR 
2.93, p < 0.001) and elevated AP (HR 1.68, p = 0.011) 
(Table 2). As far as treatment is concerned, palliative or 
curative surgery and loco-regional hepatic interventions 
combined had a significant impact on OS in this cohort 
of pNET patients.
Discussion
Prognostic and therapeutic stratification of neuroen-
docrine tumours is difficult due to the clinical and bio-
logical heterogeneity of the disease, as well as due to its 
rareness [20, 21]. Over the last decade, several classifica-
tion systems have been proposed and established, main-
ly the ENETS TNM classification and grading system, as 
well as the American Joint Committee on Cancer TNM 
staging system. These systems have been validated inde-
pendently and were incorporated in the current UICC/
WHO 2010 classification [16, 22–28]. Other parameters 
used for prognostic and therapeutic stratification in-
clude PS using ECOG has been validated in multiple ob-
servational and therapeutic studies as a predictor of out-
come.
Functional imaging studies can visualize somatostatin 
receptor (SSTR)-expression via Ga68-DOTATATE or 
DOTATOC or DOTANOC PET/CT (Positron Emission 
Tomography/Computed Tomography), or metabolic ac-
tivity detected via glucose uptake in 18F-FDG-PET/CT 
(18F-2-Fluoro-2-Deoxy-D-Glucose-PET/CT) [29, 30] as 
well as the vascularization of the disease, which might 
permit the patient to undergo local or systemic anti-an-
giogenic therapy or be treated with somatostatin ana-
logues or PRRT [31–33]. Furthermore, metabolic activity 
measured via 18F-FDG-PET/CT can stratify patients into 
different prognostic subgroups [34].
Biomarkers as well as patient and imaging character-
istics are increasingly used in the decision-making pro-
cess based on their potential prognostic value. In this con-
text, CgA is well established, but recently published stud-
ies have examined the role of circulating tumour cells, 
microRNAs and multianalyte personalized analyses to 
understand tumour biology and disease progression [35, 
36].
The aim of our multicentre retrospective cohort study 
was to evaluate metastatic pNET patients to create a strat-
ification tool that can aid the classification of disease 
prognosis.
In the present study, a median OS of 6.6 years was cal-
culated using Kaplan-Meier analysis, which is similar to 
that in previous published data [37, 38]. However, recent 
retrospective studies with a similarly high percentage of 
grade 2 tumours (∼65% in our cohort) have revealed even 
higher OS rates [28, 39]. The influence of grading on 
prognosis is demonstrated in our cohort between grade 1 
and grade 2 tumours. With regard to Ki-67 index, we used 
the established ranges stated in the ENETS-Grading sys-
tem/WHO 2010 classification [22, 26]. However, there is 
currently an ongoing scientific discussion on new Ki-67 
ranges for pNETs [28, 40, 41] and our multivariate analy-
ses of the Ki-67 index (cut-off 10%) showed that it is a 
strong prognostic marker, and also supports a redefining 
of the cut-offs. Also with regard to the prognostic impact 
of the Ki-67 index, it may have some value as a predictive 
tool, although this was not the aim of our study [42, 43].
Table 2. Mutivariate Cox analysis for factors associated with increase in risk of death
Mutivariate Cox analysis Coefficient z p value
ECOG-PS (≥2 vs. 0–1) 0.704127 2.503535 0.012*
Metastases (synchronous vs. metachronous) 0.761831 2.093995 0.036*
Histological grade (2 vs. 1) 0.416900 1.813838 0.070
Ki-67 index (≥10% vs. 1–10%) 1.078342 4.716314 <0.001***
AP (elevated vs. normal) 0.521302 2.538865 0.011*
Loco-regional treatment (yes vs. no) –0.691276 –1.935389 0.053
Surgical and loco-regional interventions (yes vs. no) –1.001395 –3.860232 <0.001***
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Additionally, the biomarker CgA was shown to sig-
nificantly affect OS in our cohort. CgA has been used for 
many decades as a biomarker for neuroendocrine disease 
activity and it appears to have a dual role. First, CgA is 
used to define biochemical response under treatment and 
was correlated with radiological disease response in sev-
eral studies, thereby emphasizing its predictive impact 
[44–46]. Second, elevated CgA may reflect hepatic tu-
mour burden, once again a strong prognostic indicator 
[45, 47]. In our study cohort, elevated CgA was associated 
with reduced OS compared with patients who had meta-
static disease and normal CgA. However, as a broad-spec-
trum-marker, CgA has limitations in terms of sensitivity, 
specificity and reproducibility [36], fuelling ongoing dis-
cussion about its usefulness and the merits of new devel-
opments in the field [35].
Furthermore, we assessed laboratory values indirectly 
influenced by the hepatic tumour burden (AP) and cell 
proliferation (LDH). An elevation of these enzymes was 
associated with reduced OS. Clancy and colleagues have 
shown similar results in their publications, where in-
creased levels of AP and LDH were also identified as pre-
dictors of earlier death [48].
Regarding the metastatic patterns observed, most pa-
tients had hepatic metastases with bilobar involvement, 
indicative of higher hepatic tumour burden and strongly 
associated with reduced OS on univariate analysis. Simi-
lar associations were seen in the PROMID trial and in a 
recent study by Panzuto et al. [49, 50]. Those patients who 
developed metachronous metastases had a favourable HR 
compared with patients with synchronous metastases. 
The surgical intervention group also benefitted from sig-
nificantly longer OS. On univariate analysis, surgery 
(both with palliative and curative intention) and loco-re-
gional hepatic interventions were identified as significant 
prognostic factors. Thus, several conclusions may be 
drawn from this: radical surgical intervention aiming to 
remove the primary tumour and/or liver metastases or 
tumour debulking resection can improve the outcome. 
This supports the conclusions of previous studies on sur-
gical intervention in pNET patients with synchronous 
liver metastases [51]. Clinically, routine primary tumour 
resection is often performed to achieve liver-only disease 
and preselected patients benefit from metastatic resection 
either with curative or palliative intent. However, this is 
not validated in prospective and randomized trials and 
should be critically discussed. Due to the retrospective 
nature of our study, there may have been a selection bias 
in which patients who were deemed suitable for surgical 
therapy usually had a smaller primary, limited metastatic 
spread and better PS. Essentially, this means that among 
the group of stage IV patients, this cohort had a better 
prognosis at the outset. Therefore, it can be assumed that 
the predominating factor leading to better survival for 
these patients was the metastatic pattern in a stage IV set-
ting. This hypothesis is supported by several other studies 
in this area, including the already mentioned series from 
Panzuto et al. [50], in which 3 distinct subgroups of met-
astatic pattern were compared. They found a statistically 
significant association of OS with the metastatic pattern, 
the risk of death increasing by 2.5 and 12.4 times for pa-
tients with bilobar liver metastases and extra-abdominal 
lesions when compared with those with unilobar liver in-
volvement (p = 0.01 and p < 0.0001, respectively). We 
presented similar results in our study and confirmed a 
better prognosis in patients with unilobar hepatic tumour 
burden.
There are some limitations to our study. Due to its ret-
rospective nature, there may have been some variation in 
the methods used to collect data over time and in the 
methodology used in the different participating centres. 
Normal ranges for laboratory values and the assays used 
vary, for example, for CgA. There is also, as with most 
retrospective analyses, the lack of a control-group and the 
possibility of selection bias with regard to the status of the 
participating hospitals as tertiary referral centres. Lastly, 
the number of missing data (especially with regard to lab-
oratory values) made meaningful multivariate analyses 
impossible, since these analyses are much more sensitive 
to missing data than are univariate analyses. Therefore, 
most of our results have not been validated in a multi-
variate setting.
However, there are very limited published data from 
multicentre studies on prognostic factors in metastatic 
pNET patients. Our study reflects the real-life situation of 
a rare disease over a period of nearly 2 decades.
Conclusion
Retrospective univariate analyses of a defined set of 
variables in a subgroup of well-differentiated pNET pa-
tients showed some statistically significant correlations 
with prognosis. Although most prognostic markers were 
not found to be independent predictors of survival on the 
multivariate analysis, they showed a tendency in that di-
rection. It is possible that these outcomes were affected, 
at least in part, by obvious laboratory data constraints, by 
the retrospective nature of our study, and by the size of 
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volving a larger patient cohort may help clarify this issue. 
In the future, the variables employed here could provide 
a prognostic score for therapeutic stratification of this 
subgroup of pNETs.
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